The Relationship between Serum Bilirubin and Elevated Fibrotic Indices among HBV Carriers: A Cross-Sectional Study of a Chinese Population

Min Du; Shanshan Zhang; Lin Xiao; Yanyan Xu; Peiyi Liu; Yuhan Tang; Sheng Wei; Mingyou Xing; Xiaoping Miao; Ping Yao
December 2016
International Journal of Molecular Sciences;Dec2016, Vol. 17 Issue 12, p2057
Academic Journal
The study probed the association between bilirubin and hepatitis B virus (HBV) infection and progression. A cross-sectional analysis of 28,500 middle aged and elderly Chinese participants was performed to analyze the differences of bilirubin in terms of hepatitis B surface antigen (HBsAg) positive or negative and the correlation between bilirubin and severity of hepatic fibrosis estimated by non-invasive indices. Bilirubin was significantly higher in the HBsAg (+) group than the HBsAg (_) group. Higher bilirubin levels were consistently associated with elevated liver fibrosis indices among HBsAg carriers. Compared with quartile 1 of total bilirubin (TBil), the multivariable-adjusted ORs (95% CIs) for elevated fibrosis indices of quartile 4 were 2.24 (95% CIs, 1.57-3.21) estimated by fibrosis 4 score (FIB-4) and 2.22 (95% CIs, 1.60-3.08) estimated by aspartate transaminase to platelet ratio index (APRI). In addition, direct bilirubin (DBil) had a stronger association with elevated liver fibrosis indices than did indirect bilirubin (IBil). Furthermore, the relationship between DBil and elevated fibrosis indices was more robust among participants who were female, overweight or had central fat distribution. These findings suggested that bilirubin levels, especially DBil, were independently associated with an increased risk of increased fibrosis indices.


Related Articles

  • Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. Osakabe, Keisuke; Ichino, Naohiro; Nishikawa, Toru; Sugiyama, Hiroko; Kato, Miho; Kitahara, Shiho; Hashimoto, Senju; Kawabe, Naoto; Harata, Masao; Nitta, Yoshifumi; Murao, Michihito; Nakano, Takuji; Shimazaki, Hiroaki; Arima, Yuko; Suzuki, Koji; Yoshioka, Kentaro // Journal of Gastroenterology;Nov2011, Vol. 46 Issue 11, p1324 

    Background: Liver stiffness (LS) has been reported to correlate with fibrosis stage (F). The correlation between LS and fibrosis stage and the reduction of LS by antiviral therapy were examined in patients with hepatitis B infection. Methods: LS was measured by FibroScan in 212 patients infected...

  • Quantification of liver fibrosis in chronic hepatitis B virus infection. Jieanu, C. F.; Ungureanu, B. S.; Săndulescu, D. L.; Gheonea, I. A.; Tudorașcu, D. R.; Ciurea, M. E.; Purcărea, V. L. // Journal of Medicine & Life;Jul-Sep2015, Vol. 8 Issue 3, p285 

    Chronic hepatitis B virus infection (HBV) is considered a global public issue with more than 78.000 people per year dying of its evolution. With liver transplantation as the only viable therapeutic option but only in end-stage disease, hepatitis B progression may generally be influenced by...

  • Classification and Progression Based on CFS-GA and C5.0 Boost Decision Tree of TCM Zheng in Chronic Hepatitis B. Xiao Yu Chen; Li Zhuang Ma; Na Chu; Min Zhou; Yiyang Hu // Evidence-based Complementary & Alternative Medicine (eCAM);2013, Vol. 2013, p1 

    Chronic hepatitis B (CHB) is a serious public health problem, and Traditional Chinese Medicine (TCM) plays an important role in the control and treatment for CHB. In the treatment of TCM, zheng discrimination is the most important step. In this paper, an approach based on CFS-GA (Correlation...

  • Management of chronic hepatitis B infection. Sundaram, Vinay; Kowdley, Kris V. // BMJ: British Medical Journal;11/7/2015, Vol. 351 Issue 8032, ph4263 

    Hepatitis B virus (HBV) is a global health problem that can lead to cirrhosis and hepatocellularcarcinoma (HCC). Although HBV vaccination has reduced the prevalence of HBV infection, the burden of disease remains high. Treatment with antiviral drugs reduces the risk of liver disease and the...

  • Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis. Schiff, Eugene; Simsek, Halis; Lee, William M.; You-Chen Chao; Sette Jr., Hoel; Janssen, Harry L. A.; Steven-Huy Han; Goodman, Zachary; Yang, Joanna; Brett-Smith, Helena; Tamez, Ricardo // American Journal of Gastroenterology;Nov2008, Vol. 103 Issue 11, p2776 

    OBJECTIVE: The efficacy and safety of entecavir in patients with chronic hepatitis B and advanced liver fibrosis/cirrhosis was assessed from three large, randomized, multicenter, phase III studies. PATIENTS AND METHODS: These studies enrolled patients (≥16 yr) with chronic hepatitis B,...

  • Herbal medicine effective on hepatitis B. Wright, Catherine // Nation's Health;Nov2002, Vol. 32 Issue 9, p4 

    Reports on the effectiveness of Chinese herbal medicine on hepatitis B. Types of clinical trials conducted by Chinese and U.S. researchers on the effectiveness of the medicine on treating the disease; Result of the trials conducted by the researchers.

  • Therapie der chronischen Hepatitis B und C in der Praxis. Panther, E.; Thimme, R. // Praxis (16618157);1/4/2012, Vol. 101 Issue 1, p37 

    Approximately 550 million people worldwide are chronically infected with hepatitis B (HBV) or hepatitis C (HCV) virus. The clinical course of HBV and HCV infection is variable and can lead to a chronic but mild hepatitis or to liver cirrhosis and hepatocellular carcinoma (HCC)¹. Therefore,...

  • Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B A Systematic Review. Buti, Marıa; Oyagüez, Itziar; Lozano, Virginia; Casado, Miguel A. // PharmacoEconomics;2013, Vol. 31 Issue 1, p63 

    Background Chronic hepatitis B is a common, progressive disease, particularly when viral replication is detected. Oral antivirals can suppress viral replication and prevent or delay the development of cirrhosis and liver-related complications. Objective The aim of this study was to...

  • HBeAg NEGATIVE CHRONIC HEPATITIS B: AN OVERVIEW. Akbar, S. M. Fazle // Hepatitis B Annual;2009, Vol. 6, p131 

    Over 350 million people worldwide are infected with hepatitis B virus (HBV), and patients with HBeAg-negative chronic hepatitis B constitute a major proportion of this population. Mutant varieties of HBV resulting from mutations in the precore or core promoter region of the viral genome give...

  • Long-Term Suppression of Viral Replication in Chronic Hepatitis B: Outcomes and Future Directions. Jae-Jun Shim // Gut & Liver;May2015, Vol. 9 Issue 3, p265 

    The author reflects on a study which investigates the effect of long-term antiviral therapy of viral replication in chronic hepatitis B (CHB) patients. Topics discussed include the disease progression, cost-effectiveness of the treatment, and DNA levels among patients. Information regarding the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics